MET and non-small cell lung carcinoma: ORR was 36.5% in 52 non-squamous NSCLC EGFR wild-type patients (52.2% in the c-Met high group and 24.1% in the c-Met intermediate group) associated with a median DOR of 6.9 months, underscoring the relevance of the magnitude of expression.